Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, 'Astellas' ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG ('Ganymed'), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016.
Under the agreement executed between Astellas and Ganymed's shareholders, Astellas paid EUR 422 million to acquire 100% of the equity in Ganymed. In addition, Ganymed's shareholders will become eligible to receive up to EUR 860 million in further contingent payments based on progress in the development of IMAB362, Ganymed's most advanced clinical program.
Through the acquisition, Astellas will expand its oncology pipeline with antibody program in the late-stage to build upon its leading oncology franchise as a platform for sustainable growth.
Astellas is still reviewing the impact of the completion of the acquisition on its financial results for the fiscal year ending March 31, 2017.
Astellas Pharma Inc. published this content on 21 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 December 2016 00:33:08 UTC.